PubRank

Michael Hutchinson

Author PubWeight™ 100.98‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011 25.66
2 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 11.29
3 Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012 6.51
4 Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009 2.82
5 A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler 2012 2.16
6 Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011 2.00
7 Yet another flawed study of self-referral? AJR Am J Roentgenol 2012 1.98
8 Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007 1.88
9 Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet 2008 1.79
10 REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain 2008 1.77
11 Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004 1.70
12 New perspectives in the natural history of multiple sclerosis. Neurology 2010 1.50
13 Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 2009 1.44
14 Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012 1.19
15 Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology 2010 1.10
16 Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 2005 1.05
17 The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry 2007 1.01
18 Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol 2011 0.95
19 Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives. J Neurol Neurosurg Psychiatry 2007 0.94
20 Effects of latitude and longitude on the population structure of Culex pipiens s.l., vectors of West Nile virus in North America. Am J Trop Med Hyg 2009 0.92
21 Temporal discrimination, a cervical dystonia endophenotype: penetrance and functional correlates. Mov Disord 2014 0.92
22 Leigh disease associated with a novel mitochondrial DNA ND5 mutation. Eur J Hum Genet 2002 0.89
23 Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test. Brain 2011 0.89
24 Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opin Pharmacother 2013 0.88
25 Comparing endophenotypes in adult-onset primary torsion dystonia. Mov Disord 2010 0.87
26 Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics 2009 0.87
27 A novel CACNA1A mutation associated with adult-onset, paroxysmal head tremor. Mov Disord 2013 0.87
28 Linkage to a known gene but no mutation identified: comprehensive reanalysis of SPG4 HSP pedigrees reveals large deletions as the sole cause. Hum Mutat 2007 0.87
29 Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia. Neurology 2004 0.86
30 New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin. J Neurol 2008 0.86
31 Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. J Neurol 2005 0.85
32 Paroxysmal torticollis and blepharospasm following bilateral cerebellar infarction. J Neurol 2006 0.85
33 Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? Mult Scler 2009 0.84
34 Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T POLG mutation. Muscle Nerve 2010 0.84
35 Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler 2013 0.83
36 A genome wide scan for association with multiple sclerosis in a N. Irish case control population. J Neuroimmunol 2003 0.82
37 Adult mosquitoes parasitized by larval water mites in Pennsylvania. J Parasitol 2012 0.82
38 Striatal morphology correlates with sensory abnormalities in unaffected relatives of cervical dystonia patients. J Neurol 2009 0.81
39 Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial. Trials 2013 0.81
40 Only low frequency event-related EEG activity is compromised in multiple sclerosis: insights from an independent component clustering analysis. PLoS One 2012 0.81
41 Inversion recovery MRI in idiopathic Parkinson disease is a very sensitive tool to assess neurodegeneration in the substantia nigra: preliminary investigation. Acad Radiol 2006 0.81
42 Evaluation of a rapid analyte measurement platform for West Nile virus detection based on United States mosquito control programs. Am J Trop Med Hyg 2012 0.81
43 Safety first, efficacy second in disease modifying therapies. Mult Scler 2011 0.80
44 Symptom overlap in anxiety and multiple sclerosis. Mult Scler 2013 0.79
45 Familial adolescent-onset scoliosis and later segmental dystonia in an Irish family. J Neurol 2004 0.79
46 Computer assessment of neurodegeneration in Parkinson disease using data fusion techniques with MR images. Acad Radiol 2003 0.79
47 Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol 2007 0.79
48 Estimating West Nile virus transmission period in Pennsylvania using an optimized degree-day model. Vector Borne Zoonotic Dis 2013 0.79
49 Molding the sensory cortex: spatial acuity improves after botulinum toxin treatment for cervical dystonia. Mov Disord 2007 0.79
50 Unusual MRI abnormalities in anti-Yo positive "pure" paraneoplastic cerebellar degeneration. J Neurol 2007 0.78
51 The effect of stability of oral anticoagulant therapy upon patient-perceived health status and quality of life. J Am Geriatr Soc 2003 0.78
52 Inherited myoclonus-dystonia and epilepsy: further evidence of an association? Mov Disord 2004 0.78
53 Using atypical symptoms and red flags to identify non-demyelinating disease. J Neurol Neurosurg Psychiatry 2011 0.77
54 GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006 0.77
55 Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination. Mov Disord 2013 0.77
56 Creutzfeldt-Jakob disease in Ireland: epidemiological aspects 1980-2002. Eur Neurol 2004 0.77
57 Is a 20% change in MSFC components clinically meaningful? Mult Scler 2007 0.77
58 In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary. Mult Scler 2013 0.77
59 Treatment adherence: what is the best that can be achieved? Int MS J 2005 0.76
60 Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders. J Neural Eng 2015 0.76
61 On the use of clusters to determine environmental influence on disease. Arch Neurol 2005 0.75
62 On the toxicity of GDNF. Toxicol Pathol 2008 0.75
63 Oestrogen therapy for multiple sclerosis: not the way forward. Int MS J 2003 0.75
64 Cervical dystonia following peripheral trauma--a case-control study. J Neurol 2004 0.75
65 The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway - Commentary. Mult Scler 2015 0.75
66 On radiology referral versus specialist referral. Radiology 2008 0.75
67 Response to comment on the article by Allen et al. 'A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers'. Mult Scler 2012 0.75
68 The best basic science paper on multiple sclerosis in 2012: commentary. Mult Scler 2013 0.75
69 A comparison of stimulus presentation methods in temporal discrimination testing. Physiol Meas 2017 0.75
70 Phenotypic diversity associated with the mitochondrial m.8313G>A point mutation. Muscle Nerve 2009 0.75
71 Cervical dystonia presenting as a phenocopy in an Irish SCA2 family. Mov Disord 2009 0.75
72 Epidemiology of Wilson's disease in Ireland. Mov Disord 2014 0.75
73 Clinical reasoning: an unusual case of papilledema after orthotopic liver transplantation. Neurology 2009 0.75
74 Application of virtual reality head mounted display for investigation of movement: a novel effect of orientation of attention. J Neural Eng 2016 0.75
75 Menstrual cycle and the temporal discrimination threshold. Physiol Meas 2017 0.75
76 Tolosa-Hunt syndrome responsive to infliximab therapy. J Neurol 2009 0.75
77 The best basic science paper in multiple sclerosis in 2014: citicoline, remyelination and neuroprotection: commentary. Mult Scler 2015 0.75
78 On false negatives in MRI studies of Parkinson disease. Mov Disord 2007 0.75